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Abnormal phosphomonoester signals in 31P MR spectra from patients with
hepatic lymphoma. A possible marker of liver infiltration and response to
chemotherapy
R.M. Dixon, P.W. Angus', B. Rajagopalan & G.K. Radda
MRC Biochemical and Clinical Magnetic Resonance Unit, andNuffield Department ofMedicine, John Radcliffe Hospital, Oxford,
OX3 9DU, UK.
Summary Hepatic infiltration by lymphoma can be difficult to detect by conventional methods. We have
studied 22 patients in vivo 31P magnetic resonance spectroscopy of the liver and compared the results with the
clinical staging and assessment of liver involvement by computed tomography (CT), ultrasound (US), and liver
function tests (LFTs). We find that the phosphomonoester (PME) to ATP, and the PME to Pi ratios are the
best indication of liver involvement as in all the patients with liver involvement apparent on CT or US, these
ratios were elevated (>2 s.d. above the control mean). Of the patients with deranged LFTs but normal CT or
US, five out of nine showed increased PME/ATP and PME/Pi ratios, and in the patients with normal LFTs
and normal CT or US, three out of eight patients had raised PME ratios. Extracts of lymphomatous lymph
nodes contain high concentrations of phosphoethanolamine which suggests that this compound is responsible
for the increase in the PME peak. Eleven patients were studied again after chemotherapy, and those with
initially raised PME/ATP and PME/Pi ratios all showed a decrease in these ratios towards normal. The
patients with initially normal ratios showed no changes.
31P magnetic resonance (MR) spectroscopic studies of human
cancers have demonstrated a variety of biochemical abnor-
malities in malignant tissues, including pH shifts and raised
phosphomonoesters (Oberhaensli et al., 1986; Cox et al.,
1988; Ng et al., 1989; Glazer et al., 1989). MR spectroscopy
therefore appears to offer a means of distinguishing between
normal and neoplastic tissue, and of monitoring cellular
energetics and biochemistry in response to treatment (Maris
et al., 1985; Glaholm et al., 1989; Ng et al., 1987).
Detection of hepatic involvement in malignancies such as
lymphoma is important as this may affect choice of treatment
or prognosis, but the sensitivity of CT scanning and US for
diagnosing diffuse liver involvement is poor (Golding, 1989)
and magnetic resonance imaging does not appear to be more
accurate than CT (Weinreb et al., 1984). Liver function tests
are frequently abnormal in patients without hepatic
infiltration (Trewby et al., 1979), and conversely the tests
may be normal in patients with clearcut disease. Open liver
biopsy may be the most reliable method for detecting
infiltration, but this invasive procedure cannot usually be
justified, and may miss areas of patchy infiltration (Goffinet
et al., 1977; Bagley et al., 1972). In contrast to the techniques
that provide structural information, MRS offers the pos-
sibilty of a direct measure of cellular function.
The current study was undertaken to determine whether
hepatic involvement with lymphoma produced biochemical
changes that could be detected by 31P MR spectroscopy of
the liver. Elevated PME/ATP and PME/Pi ratios were found
in patients with hepatic infiltration, and these ratios fell
following chemotherapy. These findings suggest that 31P
MRS is useful for assessing liver involvement and the res-
ponse to treatment in this disease.
Methods
Subjects
Twenty-two patients with recently diagnosed lymphoma were
studied by 31P MRS of the liver. The patients were selected
for the MRS study on the clinical grounds of enlarged liver
or spleen, deranged liver function tests, or extensive disease
elsewhere. The study was approved by the local Ethics Com-
mittee, and patients gave their informed consent to the MRS
investigation. Lymph node biopsy showed that eight patients
had Hodgkin's disease and 14 had non-Hodgkin's lym-
phoma. Of the patients with non-Hodgkin's lymphoma, 11
had high grade lymphoma and three had low grade disease.
Standard biochemical liver function tests (bilirubin, alkaline
phosphatase, aspartate transaminase (AST)) were performed
at least twice within 7 days of the MR study. The liver was
also imaged by CT scan and/or ultrasound scan. In addition,
two patients underwent liver biopsy (one percutaneous, and
one at laparotomy) during their initial diagnostic work-up.
We were able to obtain sufficient lymph node material from
the biopsy specimens of nine patients for in vitro MR spec-
troscopic analysis (see below).
Following the first MR investigation, 19 patients were
treated with systemic chemotherapy and three received local
deep X-ray therapy alone. Eleven of those who had chemo-
therapy underwent a further MRS study within 2 weeks of
commencing treatment.
Controls
Twenty-five healthy controls (ages 20-50) were studied by
the same 31P MRS protocol as the patients.
MR spectroscopy ofthe liver
Magnetic resonance spectra were obtained on a 1.9 Tesla,
60 cm clear bore magnet (Oxford Research Systems, Oxford,
U.K.) operating at 32.7 MHz for phosphorus. A double sur-
face coil was used (Styles, 1988) in which the receiver coil
(6.5 cm diameter) was isolated from, and positioned forward
of the transmitter coil (15 cm diameter). The subject lay on
his or her right side with the liver over the coil centre. The
field homogeneity was adjusted by observing the proton sig-
nal from tissue water. Spectra of liver were obtained free
from contamination from overlying muscle by a modification
of the rotating frame depth selection (Blackledge et al., 1987)
in which 90 transients at a pulse angle of 3 in the liver were
subtracted from 256 transients at a pulse angle of (0 is the
nominal 900 pulse angle in the region of interest, usually
450-550ps). The interpulse delay was 1 s. This technique
gave good cancellation of the overlying muscle, and hence
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the signal was obtained from a volume containing only liver.
The study could be completed in about 30 min.
The relative amounts of phosphomonoesters (PME), inor-
ganic phosphate (Pi), phosphodiesters (PDE) and adenosine
triphosphate (ATP), were quantified by measuring the ratios
of the peak areas, which were estimated by triangulation. A
broad signal underlying the phosphodiester region was re-
moved by convolution difference before each spectrum was
plotted, and the spectra were transformed with a Lorentzian-
to-Gaussian lineshape conversion to minimise peak overlap.
The nucleoside triphosphate y-P signal was used in the
calculations as a measure of ATP, as the ATP a-P peak
contains contributions from other compounds, and at the
transmitter power used (140 W), the ATP ,-P peak was
distorted by off-resonance effects. The ATP '-P peak also
contains signals from other nucleotides, especially GTP Zy-P
(about 10% of the peak area), but no corrections were made
for this, or for partial saturation effects. Spectra were also
collected at 0.1 s interpulse delay to detect changes in relaxa-
tion times of the signals.
MR spectroscopy ofextrahepatic lymph node masses
Superficial lymph node masses in the neck or groin were
studied by MR spectroscopy in three patients. A 3 cm dia-
meter surface coil was taped to the skin, over the tumour,
and spectra were collected with an interpulse delay of 2 s.
Metabolite ratios were calculated as above.
Analysis oflymph node biopsies by 31P MR spectroscopy
The lymph nodes were frozen in liquid nitrogen after ex-
cision. The tissue was powdered under liquid nitrogen and
homogenised in ice-cold perchloric acid (6% v/v, 3 ml g'
tissue). The homogenate was centrifuged, and the super-
natant was neutralised with 5M KOH. The sample was
recentrifuged, and the supernatant was lyophilised. The re-
sulting solid was dissolved in 8.6 mM EDTA, filtered, and
adjusted to pH 8.5. Fully relaxed 31p MR spectra were
obtained at 121 MHz. Composite pulse proton decoupling
was applied during acquisition, and gated off during the
relaxation delay. This ensured that the intensities were not
distorted by relaxation or nuclear Overhauser effects. A coax-
ial capillary containing methylene diphosphonate acted as a
concentration standard. Chemical shifts were referred to
glycerophosphocholine at 2.90 p.p.m. (relative to PCr at
0 p.p.m.), as this resonance is virtually unaffected by pH or
ionic strength changes, and was usually present in the lymph
node extracts. Compounds were identified from their chem-
ical shifts, pH titration behaviour and by addition of known
compounds.
Results
(1) Patients: clinicalfindings
We separated the patients into three broad groups on the
basis of the clinical, biochemical and radiological evidence, in
terms of the likelihood of hepatic involvement (Table I). In
eight patients (Group 1, patients 1-8) there was no indica-
tion of hepatic infiltration, since liver function tests and
radiological imaging were both normal. Group 3 comprised
five subjects (patients 18-22) who had been diagnosed as
having stage IV disease with hepatic spread. All had raised
alkaline phosphatase and yGT, and, in addition, two had
clearly defined patches of lymphoma tissue within the liver,
and three had features suggesting diffuse infiltration on CT
scan (Golding, 1989). All had some degree ofhepatic enlarge-
ment. Finally, there were nine patients in whom hepatic
involvement was suspected on the basis of abnormal LFTs,
but their CT scans were apparently normal apart from
hepatic enlargement in some cases (Group 2, patients 9-18).
Two of these patients subsequently underwent liver biopsy; in
both cases liver histology was normal. There was no clinical
evidence of other forms of liver disease in any ofthe patients.
Table I Clinical details of lymphoma patients
Patient Age Sex LFT CT/US Diagnosis Stage Group*
1 45 M N N NHL II 1
2 23 F N N HD III 1
3 67 M N N NHL I 1
4 23 F N N HD III 1
5 27 M N N HD III 1
6 81 F N N NHL I 1
7 65 F N N NHL III 1
8 37 M N N NHL II 1
9 16 M + N NHL III 2
10 55 M + N NHL III 2
11 21 F + N HD II 2
12 46 M + N NHL III 2
13 33 M + N HD IV 2
14 16 M + N NHL IV 2
15 52 M + N NHL III 2
16 21 M + N HD IV 2
17 22 M + N HD III 2
18 43 M + + HD IV 3
19 67 M + + NHL IV 3
20 67 F + + NHL IV 3
21 56 F + + NHL IV 3
22 60 M + + NHL IV 3
N= normal; + = abnormal; HD = Hodgkin's Disease; NHL = Non
Hodgkin's Lymphoma; *See text for definition ofGroups.
(2) MR spectroscopy
Controls A phosphorus MR spectrum from the liver of a
healthy control is shown in Figure la. The metabolite ratios
from the control group were PME/ATP = 0.37 (0.10), PME/
P,= 0.58 (0.11), PDE/ATP = 1.41 (0.33), Pi/ATP = 0.64
(0.15), (Mean (s.d.), n = 25).
Patients 31P MR liver spectra were obtained from all the 22
patients. All of the patients in Group 3 had abnormal MRS
findings. A spectrum from one of these patients is shown in
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Figure 1 a, 31p MR spectrum of the liver of a normal control
subject. b, Spectrum of the liver of a patient with hepatic lym-
phoma (Group 2). c, Spectrum of the liver of a patient with
hepatic lymphoma (Group 3). d, Spectrum from patient in c after
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Figure lc. The major abnormality in the liver spectra from all
the patients in this group was the elevation of the phos-
phomonoester (PME) peak relative to both the Pi and ATP
peaks (Figure 2). As the PME peak increased with respect to
both Pi and ATP we may assume that the levels of phos-
phomonoesters have increased, rather than a decrease in both
Pi and ATP. The changes could not be explained by altera-
tions in relaxation times of the metabolites, assessed by
comparing the peak intensities at 0.1 s and 1 s interpulse
delay. Five out of the eight patients in Group 1 had all four
metabolite ratios within 2 s.d. of control values, but three
showed elevated PME/Pi and PME/ATP ratios. The MRS
findings in patients from group 2 also varied considerably.
Three patients had completely normal spectra. Two patients
had PME/ATP ratios just outside two standard deviations of
the control mean, but their PME/Pi ratios were within the
normal range. The remaining four patients had similar ab-
normalities to those seen in Group 3 with distinct elevation
of both PME/Pi and PME/ATP (Figures lb and 2). The
other metabolite ratios (Pi/ATP and PDE/ATP) were normal
in all 22 patients (Pi/ATP = 0.68 (0.12), PDE/ATP = 1.32
(0.44), Mean (s.d.)). The pH was estimated from the chemical
shift of the Pi peak (referred to the water peak in the proton
spectrum (Ackerman et al., 1981) and was normal (pH = 7.2
(0.1)).
The MRS findings were also compared to the clinical
staging results, assessed independently by the patients' phy-
sicians (Callender et al., 1987). The results are shown in
Figure 3. While most of the patients with stage I or II disease
had normal PME ratios, patients with stage III or IV disease
had ratios varying from normal to almost four times the
normal ratio.
The chemical shift of the phosphomonoester peak (referred
to the water peak in the proton spectrum) was also related to
the PME/ATP ratio (Figure 4), being shifted to lower field at
higher ratios.
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Figure 3 a, PME/ATP ratio versus clinical stage. b, PME/Pi
ratio versus clinical stage. The staging was assessed independently
by the patients' physicians. 0 Hodgkin's disease, * non-
Hodgkin's lymphoma, high grade, non-Hodgkin's lymphoma,
low grade.
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Figure 2 a, PME/ATP ratio versus Group. b, PME/P, ratio
versus Group. Assignment of patients to each group is described
in the text. 0 Hodgkin's disease, * non-Hodgkin's lymphoma,
high grade, 0 non-Hodgkin's lymphoma, low grade.
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Figure 4 Chemical shift or the PME peak versus PME/ATP
ratio. A positive correlation exists: P<5%.
(3) Effect ofchemotherapy
Eleven patients were studied again after chemotherapy. The
results are shown in Figure Id and 5. Six of these patients
had raised PME/Pi and seven had raised PME/ATP ratios
before chemotherapy. All the patients with initially raised
PME/ATP and PME/Pi ratios showed a decrease of these
ratios, in some cases to within the normal range. These
decreases were statistically significant (P< 1%, paired t-test).
In the four patients with normal spectra before chemo-
therapy, neither the PME/Pi or the PME/ATP ratio was
affected by chemotherapy, nor were there any other changes
in the spectra.
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(4) Spectroscopy ofextrahepatic lymph node masses
The spectra of the enlarged nodes showed a large PME peak,
as in Figure 6a. The PME/ATP ratios were 2.2, 2.5 and 1.4
in the three lymph nodes.
(5) Identification ofthe monoester
A high resolution 31P MR spectrum of the acid extract of a
lymph node is shown in Figure 6b. The lymph nodes had
been frozen in liquid nitrogen after excision, but in most
cases significant ATP hydrolysis had occurred before freez-
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Figure 5 PME/P, ratio before and after chemotherapy.
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ing. The most prominent peak in the phosphomonoester
region of each spectrum was phosphoethanolamine. The
compound was identified by its pH titration behaviour and
by addition of authentic samples. The concentration ofphos-
phoethanolamine averaged 4.6 (0.9)1tmol g-' wet weight and
31 (5)% of total acid-extractable phosphorus (mean (s.d.),
n = 9).
Discussion
The improvement in outcome for patients with lymphoma
over recent years is in part due to increased accuracy in
detecting the sites of the disease, so an ability to distinguish
hepatic infiltration may help with the assessment of the
disease, and choice of treatment. This study shows that
hepatic infiltration with lymphoma is associated with eleva-
tion of the PME/ATP and PME/Pi ratios in the 3lP MR liver
spectrum. All of the patients who had hepatic lymphoma
previously diagnosed by conventional means (group 3) had
these ratios at least 2 s.d. above mean control values, and up
to four times the normal ratios. The abnormalities were not
dependent on the type of tumour (Table I) or the histological
grade (Figures 2 and 3).
The PME/ATP and PME/Pi ratios were also approx-
imately related to clinical stage (Figure 3). Four out of the 5
patients with stage I or II disease had normal ratios, whereas
those with stage III or IV disease (17 patients) had ratios
ranging from normal (five patients) to markedly elevated.
In five of the eight subjects where there was no suggestion
of liver involvement from either LFTs or CT scan (Group 1),
liver spectra were normal, even in two cases where patients
had very large extrahepatic tumour masses. In addition, three
of the nine patients who had abnormal LFTs but normal CT
scans (Group 2) had normal spectra. These findings suggest
that, in these patients, hepatic monoester levels have not
risen nonspecifically in response to disease elsewhere, and
they do not simply reflect liver function test abnormalities.
Those patients with abnormal LFTs but normal spectra may
reflect either a non-lymphomatous cause of deranged liver
function tests, or extrahepatic lymphoma causing obstruc-
tion. The finding of increased monoester levels in nine
patients who had normal CTs (Groups I and 2) may indicate
that MR spectroscopy detected hepatic infiltration that was
not apparent on CT.
An explanation is needed for the three patients in Group 1
with raised PME/Pi and PME/ATP ratios but normal LFTs.
Infiltration of the liver by lymphoma may occur either as
macronodules (detectable by CT or US) or as 'micronodules'
that cannot be detected by conventional imaging techniques.
From the present data we cannot establish whether these
patients in fact had hepatic infiltration, as liver biopsies were
not performed, for ethical reasons. Needle biopsies, however,
have been shown to be unreliable in the detection of lym-
phoma, as infiltration is often patchy. Wedge biopsies at
laparotomy or laparoscopy give more consistent results, but
these are much more invasive procedures (Goffinet et al.,
1977).
Large monoester signals have been detected in MR spectra
of a number of tumours in man, both hepatic and ex-
trahepatic. These include secondary adenocarcinoma of the
liver, Hodgkin's lymphoma, hepatoblastomas (Oberhaensli et
al., 1986), neuroblastoma (Maris et al., 1985) and carcinoid
metastases (Cox et al., 1988). The biochemical basis of these
changes is, however, unclear. An increased hepatic PME
peak is not specific to cancer, as it is also found in conditions
such as alcoholic hepatitis (Angus et al., 1990) and viral
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Figure 6 a, In vivo 31p MR (32 MHz) spectrum of an ext-
rahepatic enlarged lymph node. b, High resolution of 31p MR
spectrum (121 MHz) of the acid extract of a lymphomatous
lymph node.
hepatitis (Oberhaensli et al., 1990). In the present study we
obtained spectra from superficial malignant lymphoma mas-
ses in three patients; these spectra also showed very large
monoester peaks. High resolution 31P MR spectra of the acid
extracts of lymph nodes from nine patients revealed high
concentrations of phosphoethanolamine. Thus a likely ex-
planation for our finding is that phosphoethanolamine-rich
lymphoma cells in the liver were detected in the spectra in
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vivo. It was not possible to determine directly whether this
was the case, since at present spectroscopy in vivo cannot
resolve the monoester signal into its component peaks and no
lymphomatous liver tissue was available for extraction. The
chemical shift of the PME peak is weighted average of the
shifts of the compounds contributing to the peak. These
include phosphocholine, phosphoethanolamine, and smaller
amounts of AMP, phosphorylated sugars and glycolytic in-
termediates, both in normal liver and in tumour cells. The
increase in chemical shift as the PME/ATP ratio increases
(Figure 4) is consistent with an increase in phosphoethanola-
mine, as this compound resonates to lower field of phospho-
choline, a major component of the liver phosphomonoesters.
This supposes that sugar phosphates and AMP do not also
increase, as their chemical shifts (in vitro at pH 7.2) are close
to that of phosphoethanolamine. It could also be due to an
increase in pH in the phosphoethanolamine-rich cells, as the
frequency of this peak has been shown to titrate with pH in
the brain (Corbett et al., 1987). Maris et al. (1985) found
high levels of phosphoethanolamine in biopsies of neuroblas-
toma from infant liver, which corresponded with a high
monoester signal in the liver spectrum in vivo. If one assumes
that the hepatocytes in lymphomatous liver have normal
spectra, the proportion of hepatic infiltration can be esti-
mated from the PME/ATP ratios in normal liver and in
lymphomatous lymph nodes. By this calculation, the propor-
tion of hepatic replacement may be more than 50% in the
severely affected patients.
Liver phosphomonoester levels decreased following chemo-
therapy in all but one of the patients who had abnormally
high ratios in their initial spectra (Figure 5). The effect was
seen as early as 1 day and as late as 2 weeks after commenc-
ing treatment. Thus the timing of the second study did not
seem to be critical for detecting a response. The fact that the
spectra of patients with initially normal monoester levels
were not affected by treatment suggests that chemotherapy
does not produce a fall in the monoester levels in the normal
liver. These findings may be of clinical importance, since
detection of falling monoester levels following commence-
ment of therapy indicates that the drugs are reaching the
target cells and affecting tumour cell metabolism. The prog-
nostic significance of these changes cannot be determined
from this study because of the small numbers involved, but it
is of interest that the four patients whose liver spectra
showed persistently high monoester levels after treatment,
died subsequently of progressive disease, and those whose
levels fell into the normal range showed clinical remission.
One patient showed normal spectra throughout, but died of
progressive extrahepatic disease.
A large phosphomonoester peak in the 31P MR spectrum is
characteristic of many rapidly dividing cells, and can some-
times be correlated with proliferative activity. In cultured
human cancer cells, the PME/ATP ratio is greater during
rapid growth than at confluence (Daly et al., 1988), and in a
number of studies of solid tumours in vivo, a fall in the ratio
of PME/ATP or PME/Pi appeared to be an early marker of
tumour regression, either in response to chemotherapy, or
spontaneously (Maris et al., 1985, Glaholm et al., 1989).
Extracts of normal (rat) liver contain a large number of
compounds in the phosphomonoester region of the 31P MR
spectrum. Apart from phosphoethanolamine and phospho-
choline, these include AMP, Coenzyme A, phosphorylated
sugars, and three-carbon intermediates of glycolysis and
gluconeogenesis. The relative amounts of these depends on
the nutritional and metabolic state of the animal. The ratios
are also altered in the regenerating rat liver, in that PE/PC is
increased from 12 h to 48 h following partial hepatectomy
(Murphy, 1989). Another explanation for the large mono-
ester in our patients' spectra is therefore that the hepatocytes
themselves had increased PME levels as a result of stimula-
tion by, for instance, growth factors released from the malig-
nant cells. At present we cannot distinguish this possibility
from the possibility that the increased PME is entirely from
the infiltrating tumour cells.
The major components of the monoester peak in various
Ethanolamine
ATP ethanolamine kinase
D
> Phosphoethanolamine
CTP
CTP phosphoethanolamine
cytidylyltransferase
CDPethanolamine
d piacylglycerol etanolminephosphotransferase
Phosphatidylethanolamine
Figure 7 Enzymatic pathways of phosphoethanolamine metab-
olism in mammalian cells.
transformed cells have been identified in cell extracts as
phosphocholine and phosphoethanolamine (Evanochko et
al., 1984; Daly et al., 1988). The relative amounts of these
compounds depends not only on the tumour cell line, but
also on the conditions of growth (Navon et al., 1978; Miceli
et al., 1988). Lymphocytes in culture are rich in phos-
phoethanolamine, and we have found that reactive lymph
nodes without evidence of malignancy showed similar
amounts of phosphoethanolamine to lymphomatous ones.
We have also recently found that the concentration of phos-
phoethanolamine in lymphomatous mouse liver is linearly
related to the degree of lymphomatous infiltration (Dixon et
al., 1990).
Phosphoethanolamine and phosphocholine are synthetic
precursors of the phospholipids, phosphatidylethanolamine
and phosphatidylcholine, which are the major membrane
phospholipids. It has therefore been suggested that in rapidly
dividing cells, increased synthesis of membrane phospholipids
leads to an increase in the biosynthetic precursors. The
choline and ethanolamine pathways seem to be separately
controlled, and in general the enzymes catalysing the reac-
tions are specific to each pathway (Esko & Raetz, 1983,
pp. 207-253). In particular, CDP-choline synthesis appears
to be the rate limiting step in the synthesis of phosphatidyl-
choline, whereas the incorporation of '4C-ethanolamine into
phospholipids is not directly related to the specific activities
of the enzymes involved (Groener et al., 1979). The ethan-
olamine pathway (Figure 7) may therefore also be regulated
by the supply of substrates such as CTP or suitable
diacyl glycerols (Sundler & Akesson, 1975a). There may be
compartmentation of intermediates in both the phosphati-
dylethanolamine (Sundler & Akesson, 1975b) and phospha-
tidylcholine pathways (George et al., 1989).
Another source of the phosphoethanolamine and phos-
phocholine is the hydrolysis of the respective phospholipids
by phospholipase C, with the formation of diacylglycerols
(Pelech & Vance, 1989). Tumour promoters increase phos-
phatidylcholine turnover in HeLa cells (Guy & Murray,
1982). Diacylglycerols are increased in proliferating cells and
are second messengers involved in the activation of protein
kinase C. This, in turn, may be associated with the initiation
of cellular proliferation (Berridge, 1987).
The hepatic energy state of all the lymphoma patients
studied was normal as assessed by Pi/ATP ratio (Cunning-
ham et al., 1986) and the apparent intracellular pH. This is
perhaps not surprising, since the blood supply to the diffusely
infiltrating lymphoma cells is likely to be normal.
In conclusion, our findings suggest that elevation of the
monoester signal in the 31P MR spectrum may be useful in
the diagnosis of infiltration of the liver by lymphoma. Per-
haps more importantly, from a clinical standpoint, the mono-
ester signal may provide a useful marker of the response of
lymphoma cells to chemotherapy, and of recurrent or pro-
gressive disease.958 R.M. DIXON et al.
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